Recovering scientist turned early stage VC A biotech optimist fighting gravity

Take the Hors D’oeuvres When They’re Passed And Other Life Lessons From An “Old” CEO
April 7, 2022

By Natalie Holles, CEO of Third Harmonic Bio, as part of the From The Trenches feature of LifeSciVC Our company recently launched out of stealth with a trade media campaign in the usual outlets, which felt great until one article

Leave a comment

Biotech’s January Chill: Big Drop In New Startups
April 4, 2022

While the pace of startup formation in biotech has been accelerating over the past decade, early signs suggest the malaise in the markets is finding its way back into the venture creation ecosystem. Startups get formed, often in stealth, and

Leave a comment

Collaborating with Patient Advocacy Groups to Advance Rare Disease Awareness and Support
March 29, 2022

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Over my many years in the biopharma industry, working across disease areas, including orphan indications, I have learned that to impact patients’ lives

Leave a comment

In Defense Of Early Stage Biotech IPOs
March 28, 2022

There’s “just too many early stage companies going public”, or so goes one of the most common lamentations about the current state of the biotech market. I’ve read a good deal of venting covering this theme, including comments about VCs

Leave a comment

Innovation Ecosystem: A Year Of Risk-Off Correlations
March 21, 2022

Misery loves company, and so it goes with the stock market for the innovation ecosystem these days. The general risk-off market environment has been crushing both the emerging tech and biotech sectors alike. Last year, generalists in many ways capitulated

Leave a comment

Biotech Bears: Jumping A Lower Bar Or A Higher One?
March 17, 2022

Biotech sentiment is super bearish today, as the sector has been crushed over the last year. There’s blood in the water, especially for small and mid-cap players, and everyone’s looking for what caused the carnage. There are many factors at

Leave a comment

A Virtual Company In A Virtual World
March 16, 2022

By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC. In December 2019, I was in London meeting with my future co-founders to discuss an asset that would eventually become the cornerstone of

Leave a comment

Staying Human in the Age of Artificial Intelligence
March 9, 2022

By Jonathan Montagu, CEO of HotSpot Therapeutics, and Ramy Farid, CEO of Schrodinger, as part of the From The Trenches feature of LifeSciVC. No, your next doctor will not be a robot. Nor will an algorithm cure cancer. However, AI

Leave a comment

Going Out On A Limb: Lessons I’ve Learned Chasing My Dreams
March 2, 2022

By Deanna M. Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC One of the most common questions I get asked is how I got into the business side of the biotech industry, and in

Leave a comment

Recapturing Our Resilience
February 16, 2022

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC For anyone that’s part of a fast paced, growing organization, resilience is the key to thriving.  It supports our audacity, ability to tune

Leave a comment

Heads Up And Eyes Wide Open
February 7, 2022

By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches features of LifeSciVC When your team’s priority is to execute a well-formed plan, then a “heads down” focus is critical. We all recognize this situation, using

Leave a comment

A Tale of Two Biotech Programs
January 24, 2022

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. From the first time I heard the story of the American chestnut, I was fascinated. It is a story with threads from history, ecology,

Leave a comment